Rifampicin has an adverse effect of liver impairment, but it does not occur in all people and varies from person to person. Rifampicin is the main drug in anti-tuberculosis treatment, which has bacteriostatic and bactericidal effects, and its typical side effects may lead to liver function injury, with elevated transaminases, jaundice, and loss of appetite. Rifampicin adverse reactions leading to liver function injury usually occurs within the first few weeks of treatment, most of them are transient serum aminotransferase elevation, which can be recovered by itself in the course of treatment. Patients with pre-existing liver disease are more likely to develop liver injury when taking rifampicin. It is recommended that liver function be closely monitored during the administration of rifampicin, once every half a month in the early stage, and that the drug be stopped promptly for observation if abnormal liver function occurs.